A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause

OBJECTIVE: Menopausal vasomotor symptoms (VMS) may result from altered thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing neurons. This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Menopause
Egile Nagusiak: Fraser, Graeme L., Lederman, Samuel, Waldbaum, Arthur, Kroll, Robin, Santoro, Nanette, Lee, Misun, Skillern, Laurence, Ramael, Steven
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott-Raven Publishers 2020
Gaiak:
Original Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7147405/
https://ncbi.nlm.nih.gov/pubmed/32102086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001510
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak